Revisiting stimulant use for emotional dysregulation in attention-deficit/hyperactivity disorder (ADHD).
Brancati GE, Acierno D, Barbuti M, Elefante C, Gemignani S, Raia A, Perugi G.
Expert Rev Neurother. 2023 Jul-Dec;23(11):981-994. doi: 10.1080/14737175.2023.2263645. Epub 2023 Oct 27.
Stimulant Use Disorders.
Park TM, Haning WF 3rd.
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):461-71. doi: 10.1016/j.chc.2016.02.004. Epub 2016 Mar 28.
Prescription Stimulant Nonmedical Use Among Adolescents Evaluated for Substance Use Disorder Treatment (CHAT).
Vosburg SK, Faraone SV, Newcorn JH, Rostain AL, Findling RL, Butler SF, Govoni TD, Green JL.
J Atten Disord. 2021 Nov;25(13):1859-1870. doi: 10.1177/1087054720943283. Epub 2020 Jul 22.
Adaptation of contingency management for stimulant use disorder during the COVID-19 pandemic.
Zastepa E, Sun JC, Clune J, Mathew N.
J Subst Abuse Treat. 2020 Nov;118:108102. doi: 10.1016/j.jsat.2020.108102. Epub 2020 Aug 11.
Impact of Central Nervous System Stimulant Medication Use on Growth in Pediatric Populations with Attention-Deficit/Hyperactivity Disorder: A Review.
Troksa K, Kovacich N, Moro M, Chavez B.
Pharmacotherapy. 2019 Jun;39(6):665-676. doi: 10.1002/phar.2192. Epub 2018 Nov 21.
The potential for misuse and abuse of medications in ADHD: a review.
Clemow DB, Walker DJ.
Postgrad Med. 2014 Sep;126(5):64-81. doi: 10.3810/pgm.2014.09.2801.
Classics in Chemical Neuroscience: Methylphenidate.
Wenthur CJ.
ACS Chem Neurosci. 2016 Aug 17;7(8):1030-40. doi: 10.1021/acschemneuro.6b00199. Epub 2016 Jul 25.
Evidence-based Treatment for Stimulant Use Disorder: Time to Hit the Community.
Tardelli VS, Bisaga A, Tadonio L, Gerra G, Fidalgo TM.
Can J Psychiatry. 2023 May;68(5):370-371. doi: 10.1177/07067437221148831. Epub 2022 Dec 30.
Methamphetamine: Effects on the brain, gut and immune system.
Prakash MD, Tangalakis K, Antonipillai J, Stojanovska L, Nurgali K, Apostolopoulos V.
Pharmacol Res. 2017 Jun;120:60-67. doi: 10.1016/j.phrs.2017.03.009. Epub 2017 Mar 14.
A systematic review of the safety of lisdexamfetamine dimesylate.
Coghill DR, Caballero B, Sorooshian S, Civil R.
CNS Drugs. 2014 Jun;28(6):497-511. doi: 10.1007/s40263-014-0166-2.
